CLL1/CD33/CD38/CD7 CAR-T cell therapy

N/A

Report date: 2026/02/13 20:01:31

Base Information

Drug NameCLL1/CD33/CD38/CD7 CAR-T cell therapy
Drug Alias Nameanti-CLL1/anti-CD33/anti-CD38/anti-CD7 CAR T-cell therapy (Guangzhou Bio-gene Technology)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionLymphocyte differentiation antigen CD38 modulatorsMyeloid cell surface antigen CD33 modulatorsC-Type lectin domain family 12 member A modulators +[4] 
TargetsLymphocyte differentiation antigen CD38T-cell antigen CD7C-Type lectin domain family 12 member A +[4] 
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGuangzhou Bio-Gene Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai YaKe Biotechnology Co LtdThe Affiliated Hospital Of Xuzhou Medical UniversityXuzhou Medical University (Xzmu) +[4] 
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A